AJP - Heart Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 283: H461-H467, 2002; doi:10.1152/ajpheart.00701.2001
0363-6135/02 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, H. L.
Right arrow Articles by Lew, W. Y. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, H. L.
Right arrow Articles by Lew, W. Y. W.
Vol. 283, Issue 2, H461-H467, August 2002

TRANSLATIONAL PHYSIOLOGY
Lipopolysaccharide induces apoptosis in adult rat ventricular myocytes via cardiac AT1 receptors

Hai Ling Li*, Jun Suzuki*, Evelyn Bayna, Fu-Min Zhang, Erminia Dalle Molle, Aaron Clark, Robert L. Engler, and Wilbur Y. W. Lew

Cardiology Section, Department of Medicine, Veterans Affairs, San Diego Healthcare System, and University of California, San Diego, San Diego, California 92161


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Lipopolysaccharide (LPS) from gram-negative bacteria circulates in acute, subacute, and chronic conditions. It was hypothesized that LPS directly induces cardiac apoptosis. In adult rat ventricular myocytes (isolated with depyrogenated digestive enzymes to minimize tolerance), LPS (10 ng/ml) decreased the ratio of Bcl-2 to Bax at 12 h; increased caspase-3 activity at 16 h; and increased annexin V, propidium iodide, and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling staining at 24 h. Apoptosis was blocked by the caspase inhibitor benzyloxycarbonyl-valine-alanine-aspartate fluoromethylketone (Z-VAD-fmk), captopril, and angiotensin II type 1 receptor (AT1) inhibitor (losartan), but not by inhibitors of AT2 receptors (PD-123319), tumor necrosis factor-alpha (TNFRII:Fc), or nitric oxide (NG-monomethyl-L-arginine). Angiotensin II (100 nmol/l) induced apoptosis similar to LPS without additive effects. LPS in vivo (1 mg/kg iv) increased apoptosis in left ventricular myocytes for 1-3 days, which dissipated after 1-2 wk. Losartan (23 mg · kg-1 · day-1 in drinking water for 3 days) blocked LPS-induced in vivo apoptosis. In conclusion, low levels of LPS induce cardiac apoptosis in vitro and in vivo by activating AT1 receptors in myocytes.

endotoxemia; programmed cell death; cardiac renin-angiotensin; angiotensin II


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

LIPOPOLYSACCHARIDE (LPS) from gram-negative bacteria activates multiple cells to release cytokines, nitric oxide (NO), and other mediators with potent pathophysiological effects. Because cytokines [e.g., tumor necrosis factor-alpha (TNF-alpha ), interleukin (IL)-1beta , IL-6, and interferon (IFN)-gamma ] and NO depress cardiac function (21) and induce apoptosis in cardiac myocytes (24), it has been assumed that secondary mediators are responsible for the cardiotoxic effects of LPS. However, cardiac myocytes are sensitive to the direct effects of low levels of LPS, independently of mediators released from noncardiac myocytes. We found that clinically relevant levels of LPS (low ng/ml) activate cardiac myocytes within hours to depress myofilament responsiveness to calcium (41) and impair cell volume regulation (30). Cardiac myocytes may be directly sensitive to LPS due to the expression of Toll-like receptor 4 (11), the transmembrane component of the LPS receptor (3).

Apoptosis, an energy-dependent process of programmed cell death, is increased in heart failure from multiple causes (18), including sepsis (31). In sepsis, it is unknown whether cardiac apoptosis is caused by LPS itself or is a consequence of secondary effects activated by LPS. If low levels of LPS induce cardiac apoptosis, this has important implications because LPS circulates in several subacute and chronic conditions with less prominent activation of secondary mediators than in sepsis. Decompensated heart failure (32), pancreatitis, liver disease, chronic infections, smoking, and exercise (15), for example, are associated with plasma LPS levels in the picograms per milliliter to the nanograms per milliliter range.

It was hypothesized that low levels of LPS induce apoptosis in cardiac myocytes. The rationales for this hypothesis were the following points. First, cardiac apoptosis may occur in subacute or chronic conditions associated with circulating LPS. Second, blockade of secondary mediators may not prevent LPS-induced cardiac apoptosis. This is analogous to the failure for inhibitors of TNF-alpha , IL-1beta , platelet-activating factor, bradykinin, prostaglandins (43), and NO (14) to reduce mortality in sepsis and septic shock in several large, prospective, randomized, double-blind, multicenter trials (27). Finally, the mechanisms and relevance of cell activation are critically dependent on LPS level. For example, LPS induces apoptosis in association with cardiac TNF-alpha (6), but it requires microgram per milliliter levels of LPS to induce TNF-alpha release from adult cardiac myocytes (19). This is several orders of magnitude higher than LPS levels found in most clinical conditions (15, 33).

The mechanisms for LPS-induced apoptosis were examined in isolated, adult cardiac myocytes to minimize confounding secondary effects from nonmyocytes. Stringent conditions were required to limit inadvertent exposure to LPS, including depyrogenation of the digestive enzymes. Standard enzymes used for cell isolation are contaminated with 100-300 ng/ml LPS, which is sufficient to decrease the sensitivity to LPS by two to three orders of magnitude (29) and activate TNF-alpha synthesis (38) in cardiac myocytes. Depyrogenation of digestive enzymes allow mechanisms to be evaluated using clinically relevant levels of LPS. This study demonstrates that LPS induces apoptosis by activating AT1 receptors in cardiac myocytes. The same findings occur with LPS in vivo, with low-dose LPS (without hemodynamic effects) inducing apoptosis in left ventricular myocytes.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Experiments were performed in accordance with the institutional guidelines and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Cardiac myocyte isolation and treatment. Adult Sprague-Dawley rats (250-400 g, either sex) were anesthetized with 40 mg/kg intraperitoneal pentobarbital sodium. The heart was excised and perfused with 15-30 mg/kg depyrogenated collagenase B and protease that contained <0.3-0.5 ng/ml LPS when measured by Limulus amobocyte lysate test (QCL-1000, BioWhittaker; Walkersville, MD) (29). These methods yield ventricular myocytes with 70-85% viability (29, 41). Myocytes were plated on multichambered plates or dishes, precoated with laminin 2 µg/cm2, at a density of 105 cells/cm2 in Dulbecco's modified Eagle's medium without L-glutamine or phenol red, supplemented with 10 mmol/l HEPES, 3.7 mg/ml NaHCO3, 1 mg/ml glucose, 0.11 mg/ml sodium pyruvate, 2 mg/ml bovine serum albumin, 2 mmol/l L-carnitine, 5 mmol/l creatine, 5 mmol/l taurine, 1% penicillin-streptomycin, and 1% gentamycin at 37°C in 5% CO2. Myocytes were incubated for 24 h with LPS (Escherichia coli 055, LPS no. B5, lot 2039F, List Biological Laboratories; Cambell, CA) and/or angiotensin II (ANG II), preceded by 1-h exposure to inhibitors including captopril, PD-123319, NG-monomethyl-L-arginine (L-NMMA) (all from Sigma Chemical; St. Louis, MO), losartan (a kind gift from Merck and DuPont, Rahway, NJ), TNFRII:Fc (a kind gift from Immunex; Seattle, WA), or benzyloxycarbonyl-valine-alanine-aspartate fluoromethylketone (Z-VAD-fmk, R&D Systems; Minneapolis, MN).

Assays and Western blotting. Slide-based laser scanning cytometry (Compucyte; Cambridge, MA) was performed on myocytes stained with propidium iodide (PI) and annexin V (FITC) using Apoptosis Detection kit (R&D Systems). The PI and FITC-annexin-V integrals estimated the percentage of total cells that were alive (PI negative, annexin V negative) in early or late-stage apoptosis (PI dim or bright, annexin V positive) and necrosis (PI bright, annexin V negative) (20).

Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assays were performed on myocytes fixed with 4% formalin phosphate-buffered saline using CardioTACS In Situ Apoptosis Detection kit (R&D Systems). At least 2,000 cells were scored from each group with the observer blinded to the treatment condition. Caspase-3 activity was measured with FluorAce Apopain Assay Kit (Bio-Rad Laboratories; Richmond, CA). Protein content was determined using a standard colorimetric assay (BCA, Pierce Chemical; Rockford, IL). Immunoblot assay of Bax and Bcl-2 gene products were performed as described (28), with proteins quantitated by video densitometry with Alpha Innotech's IA-200 Image Analysis software.

In vivo model. Rats were conditioned to allow measurement of blood pressure by tail cuff. Blood pressure was measured before and 15, 30, and 45 min, and 1, 2, 4, and 24 h after LPS (1 mg/kg) or saline injection into a tail vein. Rats were euthanized for heart excision. The heart was rinsed in cold saline, fixed in 3.7% formaldehyde solution for 24 h, paraffin embedded, and then sliced with 5-µm thickness cross-sections mounted on glass slides.

Photomicrographs were obtained with a digital camera (Slider Spot-2, Diagnostic Instruments; Sterling Heights, MI) mounted on an inverted microscope (Nikon Eclipse TE300; Tokyo, Japan). Images of six to eight contiguous sections of the left ventricular anterior free wall at the midventricular level were obtained to represent a transmural section. Digital images were computer processed with NIH Image to count TUNEL-positive stained cardiomyocyte nuclei and total number of nuclei in a nuclease pretreated section from the same region. The area of each section was planimetered to calculate the average transmural density of nuclei (nuclei per µm2), TUNEL-positive stained nuclei (per µm2), and rate of TUNEL-positive nuclei (per 106 nuclei).

Statistical analysis. Results were compared by one- or two-way repeated measures ANOVA in protocols where myocytes from each rat were subdivided into separate dishes to test individual treatments (n = 1 for each rat heart). Results were analyzed by t-test, one- or two-way ANOVA in protocols without matched myocyte data from the same animal. Post hoc comparisons were performed with Student-Newman-Keuls methods. All results are expressed as means ± SE. Statistical significance indicates P < 0.05.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

LPS induces apoptosis in cardiac myocytes. Adult rat ventricular myocytes were exposed for 24 h to: 1) vehicle (control), 2) LPS (100 ng/ml), or 3) a metabolic inhibition/recovery protocol (20 mmol/l 2-deoxyglucose and 1 mmol/l NaCN solution at pH 6.6 for 40 min, with recovery for 24 h), which we found to induce apoptosis (13). With the use of slide-based laser scanning cytometry as previously described (20), the percentage of myocytes in early apoptosis (positive annexin V, dimly positive PI staining) increased with LPS (12.8 ± 2.1%, means ± SE), but not with metabolic inhibition/recovery (8.9 ± 1.7%) compared with control (4.7 ± 0.5%, P < 0.05, one-way repeated measures ANOVA, n = 6). In contrast, myocytes in late apoptosis (positive annexin V, brightly positive PI staining) increased with metabolic inhibition/recovery (25.0 ± 5.9%), but not with LPS (14.5 ± 1.5%) compared with control (8.9 ± 1.3%, P < 0.05).

Apoptosis was confirmed with increased TUNEL staining from 4 to 24 h, which was greater with 10-100 than with 0-1 ng/ml LPS (Fig. 1, P < 0.05, two-way repeated measures ANOVA on two factors, n = 5 experiments). Isolated myocyte preparations contain few (<= 5%) nonmyocytes (29), including cardiac fibroblasts, which are small and may overlie myocytes. This did not cause overestimation of TUNEL-stained myocytes. Cardiac fibroblasts grown to 60-80% confluence had low levels of apoptosis by PI staining (0.3-0.7% out of >10,000 cells analyzed by FACS), which was similar after exposure to 10 ng/ml LPS or vehicle for 24 h (n = 2 experiments).


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 1.   Percent terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)-positive stained myocytes (means ± SE, n = 5) increased with lipopolysaccharide (LPS) dose (1-100 ng/ml, P < 0.01) and time (4 vs. 24 h, P < 0.05). At 24 h, TUNEL staining was greater with 10-100 ng/ml LPS than with 0-1 ng/ml LPS.

Mechanisms for LPS-induced cardiac apoptosis. It was hypothesized that LPS-induced cardiac apoptosis involves ANG II because ANG II induces apoptosis in adult myocytes (17), and we found an interaction between LPS and ANG II through AT1 receptors in cardiac myocytes (42). In Fig. 2, cardiac myocytes incubated for 24 h with LPS (100 ng/ml) and/or ANG II (100 nmol/l) had similar increases in TUNEL staining without additive effects (P < 0.05 compared with control myocytes, one-way repeated measures ANOVA, n = 8 experiments). Adding losartan (1 µmol/l) 1 h before LPS and/or ANG II completely blocked apoptosis (P = not significant compared with control myocytes). These findings suggest that LPS induces apoptosis by activation of cardiac AT1 receptors.


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 2.   Cardiac myocytes incubated for 24 h with LPS (100 ng/ml) and/or angiotensin II (ANG II, 100 nmol/l) had increased TUNEL staining (means ± SE, n = 8) compared with control (vehicle) (P < 0.05), which were blocked by the selective AT1 inhibitor losartan (1 µmol/l).

These results were confirmed by measuring caspase-3 activity. In a pilot study, caspase-3 activity in myocytes increased with a peak at 16 h compared with 4, 8, and 24 h after LPS (10 ng/ml). Figure 3 shows that after 16 h, LPS (10 ng/ml) increased caspase-3 activity compared with vehicle, which was blocked by adding losartan (1 µmol/l) 1 h before LPS (P < 0.05, two-way repeated measures ANOVA, P < 0.05 for interaction between LPS and losartan, n = 10 experiments). ANG II (100 nmol/l) produced similar effects as LPS. In two experiments, ANG II increased caspase-3 activity 2.2- and 1.9-fold compared with vehicle.


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 3.   LPS (10 ng/ml) increased caspase-3 activity in myocytes (means ± SE, n = 10) after 16 h compared with vehicle (control, P < 0.05), which was blocked by losartan (1 µmol/l).

LPS-induced apoptosis involves activation of cardiac AT1 receptors. Myocytes incubated for 24 h with LPS (10 ng/ml) had increased TUNEL staining (8.74 ± 0.39%) compared with control (5.97 ± 0.58), which was not blocked by PD-123319 (1 µmol/l, selective AT2 receptor inhibitor) added 1 h before LPS (8.34 ± 0.76%) (P < 0.05, one-way repeated measures ANOVA, n = 7 experiments). PD-123319 alone had no effect (5.41 ± 0.52%). In contrast, adding captopril (1 µmol/l) 1 h before LPS blocked the increase in TUNEL staining (5.85 ± 0.57%), whereas captopril alone had no effect (4.72 ± 0.66%) (n = 6 experiments).

Because TNF-alpha has been reported to mediate LPS-induced apoptosis (6), myocytes were incubated for 24 h with or without LPS (10 ng/ml), soluble dimeric TNF-alpha p75:Fc fusion protein (TNFRII:Fc, 0.5 µg/ml), losartan (1 µmol/l), or the caspase inhibitor Z-VAD-fmk (100 µmol/l) (inhibitors added 1 h before LPS). Figure 4 shows LPS-induced apoptosis was blocked by losartan and Z-VAD-fmk (P < 0.05, one-way repeated measures ANOVA, n = 8 experiments), but not by TNFRII:Fc. Thus low-dose LPS activated AT1 receptors to induce apoptosis, without involving TNF-alpha .


View larger version (35K):
[in this window]
[in a new window]
  		Fig. 4.   TUNEL staining (means ± SE, n = 8) in cardiac myocytes incubated with vehicle (control), LPS (10 ng/ml), tumor necrosis factor-alpha (TNF-alpha ) p75:Fc fusion protein (TNFRII:Fc, 0.5 µg/ml), losartan (1 µmol/l), or benzyloxycarbonyl-valine-alanine-aspartate fluoromethylketone (Z-VAD-fmk, 100 µmol/l) for 24 h. LPS-increased TUNEL staining that was not blocked by TNFRII:Fc but was blocked by losartan or Z-VAD-fmk.

LPS-induced apoptosis was not NO mediated. The increase in TUNEL staining at 24 h with 10 ng/ml LPS (8.45 ± 2.55%) compared with control (5.40 ± 1.47%) was not blocked by adding the NO synthase inhibitor L-NMMA (1 mmol/l) 1 h before LPS (8.30 ± 1.83%), whereas L-NMMA alone had no effect (4.48 ± 0.86%) (P < 0.05, two-way repeated measures ANOVA, n = 4 experiments).

Both LPS (10 ng/ml) and ANG II (100 nmol/l) decreased the ratio of the antiapoptotic protein Bcl-2 relative to the apoptotic protein Bax (Fig. 5). This was primarily related to a decrease in Bcl-2, with little or no change in Bax. At 12 h (time of peak change in a pilot study), Bcl-2 decreased 28 ± 7% with LPS and 40 ± 6% with ANG II compared with vehicle (control). In both cases, changes in Bcl-2 were greater than changes in Bax (P < 0.05, one-way ANOVA, n = 6 experiments), with no difference between LPS and ANG II responses.


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 5.   Cardiac myocytes incubated for 12 h with vehicle (control), LPS (10 ng/ml), and ANG II (100 nmol/l). Representative raw gel data are shown on top with group data (means ± SE, n = 6) below. Both LPS and ANG II induced greater changes (compared with control) in the antiapoptotic protein Bcl-2 than the apoptotic protein Bax (P < 0.05), with no difference between LPS and ANG II effects for either Bcl-2 or Bax.

LPS induces cardiac apoptosis in vivo. The in vivo effects of LPS were evaluated by injecting either LPS (1 mg/kg) or saline into a tail vein (n = 6 rats each) and then examining the heart after 24 h for apoptosis in left ventricular nuclei. Neither LPS nor saline caused distress or affected systolic blood pressure after 15, 30, or 45 min, and 1, 2, 3, 4, 5, or 24 h (measured in 4 rats with each treatment). After 24 h, the rate of TUNEL-positive stained nuclei in the left ventricle was 1.9 ± 0.3-fold higher in LPS-treated than saline-treated rats (610 ± 87 vs. 362 ± 70 positive nuclei/106 nuclei, P = 0.05, t-test).

The time course for apoptosis was studied in rats at 12 h, 1, 2, 3, 7, and 14 days after a single injection of LPS (1 mg/kg) or saline (n = 3 rats each with LPS or saline at each time period). Figure 6 shows that a single injection of LPS increased TUNEL-stained nuclei for 12 h to 3 days, but not after 1-2 wk compared with saline controls (Fig. 6, P < 0.05, univariate ANOVA with test of linear trends).


View larger version (12K):
[in this window]
[in a new window]
  		Fig. 6.   A single intravenous injection of LPS (1 mg/kg) in vivo increased TUNEL-stained left ventricular nuclei for 3 days (but not 1-2 wk) compared with saline-injected control rats (P < 0.05, univariate ANOVA with test of linear trends, n = 3 for each treatment at each time point).

To determine whether LPS induced cardiac apoptosis in vivo by the same AT1 receptor-mediated mechanism as LPS in vitro, four groups of rats (n = 6 per group) were injected by tail vein with: 1) saline (control), 2) LPS (1 mg/kg), 3) saline after 3 days pretreatment with losartan (23 ± 2 mg · kg-1 · day-1 added to drinking water) (losartan group), or 4) LPS (1 mg/kg) after 3 days pretreatment with losartan (LPS + losartan group). Three days of losartan pretreatment decreased systolic blood pressure slightly from 119 ± 1 to 117 ± 1 mmHg (P < 0.05, paired t-test). Neither LPS nor saline injections caused distress or altered systolic blood pressure between 15 min and 24 h in any group, as shown in Table 1 (P = not significant, one-way repeated measures ANOVA). Figure 7 shows that LPS increased TUNEL staining in left ventricular nuclei after 24 h compared with control, which was blocked in rats pretreated with losartan (P < 0.001, two-way ANOVA, P < 0.01 for interaction between LPS and losartan). Thus, similar to in vitro results, LPS in vivo induced an approximately twofold increase in apoptosis in cardiac nuclei after 24 h, which was blocked by inhibiting AT1 receptors.

                              
View this table:
[in this window]
[in a new window]
  		Table 1.   Systolic blood pressures with and without LPS and losartan over a 24-h period



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 7.   Rates of TUNEL-positive stained left ventricular nuclei (means ± SE, n = 6) for the same four groups of rats shown in Table 1. After 24 h, LPS (1 mg/kg iv) increased TUNEL staining but not in rats pretreated with losartan (23 mg · kg-1 · day-1) for 3 days before LPS.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

This study demonstrated that low levels of LPS induce apoptosis in cardiac myocytes in vitro and in vivo by activation of cardiac AT1 receptors. In cardiac myocytes, LPS decreased the ratio of antiapoptotic Bcl-2 to proapoptotic Bax proteins at 12 h; increased caspase-3 activity at 16 h; and increased apoptosis at 24 h with twofold increases in annexin V, propidium iodide, and TUNEL staining. ANG II produced similar changes as LPS without additive effects. LPS-induced apoptosis was completely blocked by inhibiting AT1 receptors (losartan) or angiotensin-converting enzyme (captopril), but not by inhibiting AT2 receptors (PD-123319).

LPS in vivo also induced an approximately twofold increase in apoptosis at 24 h, which was abolished by losartan. A single dose of LPS in vivo that caused no distress and did not affect blood pressure was sufficient to increase cardiac apoptosis for 1-3 days. LPS induced apoptosis in left ventricular myocytes with rates of ~600-700 nuclei per 106 nuclei. This is similar to apoptotic rates (<1%) found in several human and animal models of acute and chronic heart failure (18). The significance of these rates depends on the duration of apoptosis. If apoptosis is completed within 24 h, for example, the percentage of myocytes undergoing apoptosis over 3 days would be threefold higher than the rate of apoptosis measured at a single time point. In conditions associated with recurrent or chronic exposure to subclinical levels of LPS (e.g., teeth cleaning, smoking, periodontal disease, and chronic infections), recurrent episodes of apoptosis may lead to cumulative damage.

LPS may activate cardiac myocytes to release TNF-alpha or NO to mediate apoptosis in an autocrine manner. However, neither TNF-alpha nor NO contributed significantly to the apoptosis induced by low levels of LPS. High micrograms per milliliter of LPS induce TNF-alpha production in cardiac myocytes in vivo and in vitro (12, 19). This may cause apoptosis that is blocked by TNFRII:Fc (6). TNF-alpha may have a bifunctional role and also protect against cardiac apoptosis (26). In the current study, TNF-alpha played no role in mediating apoptosis induced by low levels of LPS. LPS-induced TNF-alpha did not play a protective role either, because TNFRII:Fc did not exacerbate apoptosis.

The minimal role of cardiac TNF-alpha is not surprising because overexpression of TNF-alpha in a transgenic model is associated with only rare myocyte apoptosis (25), and TNF-alpha alone does not induce apoptosis in neonatal cardiac myocytes in vitro (16). Furthermore, it requires three orders of magnitude higher LPS doses to induce TNF-alpha release from adult compared with neonatal myocytes (10 µg/ml vs. 10 ng/ml LPS) (39), which are well beyond LPS levels in most clinical conditions. The stringent measures used in this study to minimize LPS exposure, including enzyme depyrogenation, may modify the role of LPS-induced TNF-alpha . Otherwise, exposure to LPS contaminants in collagenase can cause baseline activation of TNF-alpha in isolated cardiac myocytes during cell isolation (39). TNF-alpha did not mediate apoptosis induced by low levels of LPS, but this does not exclude contributions by TNF-alpha under other circumstances. For example, high levels of LPS may upregulate cardiac TNF-alpha and contribute to apoptosis by additional mechanisms.

Low levels of LPS activate NO-mediated pathways in cardiac myocytes (30, 41), and cytokine-induced NO can induce apoptosis in neonatal (16) and adult cardiac myocytes (1). NO can play a bifunctional role with either proapoptotic or antiapoptotic effects (22). In this study, the NO synthase inhibitor L-NMMA neither attenuated nor exacerbated LPS-induced apoptosis, indicating that cardiac NO was not a major mediator.

It was hypothesized that LPS-induced apoptosis is mediated through the cardiac renin-angiotensin system. ANG II activates AT1 receptors to induce apoptosis in neonatal (5) and adult (17, 35) cardiac myocytes. This is blocked by losartan, but not by PD-123319. ANG II induces caspase-3 activation in adult cardiac myocytes (35). In spontaneously hypertensive rats, apoptosis in left ventricular myocytes increase with age in direct relation to the tissue angiotensin-converting enzyme activity (7). This is associated with overexpression of Bax-alpha protein and is inhibited by losartan (10). In diabetic cardiomyopathy (streptozotocin model), cardiac myocyte apoptosis increases in association with upregulation of angiotensinogen, renin, AT1 receptors, and ANG II production, which are attenuated with losartan (9).

Cardiac myocytes contain key components of tissue renin-angiotensin, including angiotensinogen, renin, angiotensin-converting enzyme, and AT1 receptors (8). Stretch of cardiac myocytes causes release of ANG II in a bimodal pattern (initial peak at 1 h, slower increase over 20 h) to induce apoptosis by a p53-mediated mechanism that is blocked by losartan (28). The tumor suppressor protein p53 triggers apoptosis by increasing cardiac myocyte expression of angiotensinogen, AT1 receptors, and increasing Bax relative to Bcl-2 (34). ANG II increases the ratio of Bax to Bcl-2 protein, which is attenuated, but not eliminated, by losartan (35). This suggests that changes in Bax and Bcl-2 contribute to, but are not solely responsible for, ANG II-induced apoptosis. The effects of inhibitors of angiotensin-converting enzyme or AT1 receptors on LPS-induced changes in Bcl-2 and Bax protein were not examined in the current study. However, LPS-induced apoptosis was blocked by captopril or losartan, with all LPS effects mimicked by ANG II.

The novel finding in this study is that LPS activates tissue renin-angiotensin to induce apoptosis in cardiac myocytes. There are scant data implicating LPS activation of the cardiac renin-angiotensin system. LPS in vivo increases angiotensinogen mRNA after 9-17 h in several organs, including the heart (23). LPS downregulates AT2 receptors in cardiac fibroblasts (36) but increases AT1 receptors in vascular smooth muscle (4). In contrast to these sparse reports for LPS, there is considerable evidence for activation of the cardiac renin-angiotensin system by humoral (e.g., glucocorticoids, estrogen, and thyroid hormone) and mechanical (e.g., myocyte stretch or altered wall stress) factors (8).

The current and prior studies demonstrate that cardiac myocytes are highly sensitive to low nanograms per milliliter of LPS, which depress myofilament sensitivity to calcium (41), impair cell volume regulation (30), and induce apoptosis. LPS activates cells by a complex interplay between soluble and cell surface recognition proteins for LPS (e.g., LPS binding protein, soluble CD14, and membrane-bound CD14) (37) and Toll-like receptor 4. Toll-like receptor 4 plays a key role in transmembrane signaling to LPS (3) and is expressed abundantly on cardiac myocytes (11). These receptors make cells sensitive to low levels of LPS by activating unique signaling pathways. Higher levels of LPS may overwhelm this system to activate cardiac myocytes by nonspecific mechanisms that lack clinical relevance for most conditions.

The direct cardiac effects of LPS are clinically relevant because picograms per milliliter to low nanograms per milliliter of plasma LPS levels occur acutely in bacteremia, sepsis, septic shock, pancreatitis, and acute respiratory distress syndrome (15, 33), and subacutely in decompensated heart failure (32), cirrhosis, chronic infections (e.g., lung, urinary tract or periodontal disease), and smoking (40). In this study, low doses of LPS in vivo caused no distress or change in blood pressure but were sufficient to induce cardiac apoptosis for days. Apoptosis may contribute to the cumulative loss of cardiac myocytes because myocytes are postmitotic cells [notwithstanding recent evidence to the contrary (2)]. The importance of a twofold increase in cardiac apoptosis may be magnified in several conditions associated with recurrent or chronic circulating LPS.

In summary, clinically relevant levels of LPS directly induce cardiac myocytes to undergo apoptosis by activation of the cardiac renin-angiotensin system. Selective blockade of AT1 receptors effectively blocks LPS-induced cardiac apoptosis in vitro and in vivo. In conditions with sustained or recurrent endotoxemia, LPS may accelerate the loss of cardiac myocytes by apoptosis.


    ACKNOWLEDGEMENTS

This research was supported by the Medical Research Service, Department of Veterans Affairs, Grant-in-Aid from the American Heart Association, Astra-Merck, (9650584N) and by Tobacco-Related Disease Research Program Grant TRDRP 9RT-0166.


    FOOTNOTES

* H. L. Li and J. Suzuki contributed equally to this work.

Address for reprint requests and other correspondence: W. Y. W. Lew, Cardiology Section 111A, VA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161 (E-mail: wlew{at}ucsd.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

10.1152/ajpheart.00701.2001

Received 7 August 2001; accepted in final form 11 April 2002.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Arstall, MA, Sawyer DB, Fukazawa R, and Kelly RA. Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation. Circ Res 85: 829-840, 1999[Abstract/Free Full Text].

2.   Beltrami, AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Betrami CA, and Anversa P. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 344: 1750-1757, 2001[Abstract/Free Full Text].

3.   Beutler, B. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 12: 20-26, 2000[Web of Science][Medline].

4.   Burnier, M, Centeno G, Waeber G, Centeno C, and Burki E. Effect of endotoxin on the angiotensin II receptor in cultured vascular smooth muscle cells. Br J Pharmacol 116: 2524-2530, 1995[Web of Science][Medline].

5.   Cigola, E, Kajstura J, Li B, Meggs LG, and Anversa P. Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res 231: 363-371, 1997[Web of Science][Medline].

6.   Comstock, KL, Krown KA, Page MT, Martin D, Ho P, Pedraza M, Castro EN, Nakajima N, Glembotski CC, Quintana PJ, and Sabbadini RA. LPS-induced TNF-alpha release from and apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J Mol Cell Cardiol 30: 2761-2775, 1998[Web of Science][Medline].

7.   Diez, J, Panizo A, Hernandez M, Vega F, Sola I, Fortuno MA, and Pardo J. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension 30: 1029-1034, 1997[Abstract/Free Full Text].

8.   Dostal, DE, and Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 85: 643-650, 1999[Abstract/Free Full Text].

9.   Fiordaliso, F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, and Kajstura J. Myocyte death in streptozotocin-induced diabetes in rats is angiotensin II-dependent. Lab Invest 80: 513-527, 2000[Web of Science][Medline].

10.   Fortuno, MA, Zalba G, Ravassa S, D'Elom E, Beaumont FJ, Fortuno A, and Diez J. p53-mediated upregulation of BAX gene transcription is not involved in Bax-alpha protein overexpression in the left ventricle of spontaneously hypertensive rats. Hypertension 33: 1348-1352, 1999[Abstract/Free Full Text].

11.   Frantz, S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, and Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104: 271-280, 1999[Web of Science][Medline].

12.   Giroir, BP, Johnson JH, Brown T, Allen GL, and Beutler B. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 90: 693-698, 1992[Web of Science][Medline].

13.   Gottlieb, RA, Gruol DL, Zhu JY, and Engler RL. Preconditioning rabbit cardiomyocytes: role of pH, vacuolar proton ATPase, and apoptosis. J Clin Invest 97: 2391-2398, 1996[Web of Science][Medline].

14.   Grover, R, Lopez A, Lorente J, Steingrub J, Bakker J, Wilatts S, McLuckie A, Takala J, and International 546C88 Septic Shock Study Group Multi-center, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 27: A33, 1999.

15.   Hurley, JC. Endotoxemia: methods of detection and clinical correlates. Clin Microbiol Rev 8: 268-292, 1995[Abstract/Free Full Text].

16.   Ing, DJ, Zang J, Dzau VJ, Webster KA, and Bishopric NH. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res 84: 21-33, 1999[Abstract/Free Full Text].

17.   Kajstura, J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, and Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29: 859-870, 1997[Web of Science][Medline].

18.   Kang, PM, and Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res 86: 1107-1113, 2000[Free Full Text].

19.   Kapadia, S, Lee J, Torre-Amione G, Birdall HH, Ma TS, and Mann DL. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 96: 1042-1052, 1995[Web of Science][Medline].

20.   Karwatowska-Prokopczuk, E, Nordberg JA, Li HL, Engler RL, and Gottlieb RA. Effect of vacuolar proton ATPase on pHi, Ca2+, and apoptosis in neonatal cardiomyocytes during metabolic inhibition/recovery. Circ Res 82: 1139-1144, 1998[Abstract/Free Full Text].

21.   Kelly, RA, Balligand JL, and Smith TW. Nitric oxide and cardiac function. Circ Res 79: 363-380, 1996[Free Full Text].

22.   Kim, YM, Bombeck CA, and Billiar TR. Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 84: 253-256, 1999[Free Full Text].

23.   Klett, C, Hellmann W, Ganten D, and Hackenthal E. Tissue distribution of angiotensinogen mRNA during experimental inflammation. Inflammation 17: 183-197, 1993[Web of Science][Medline].

24.   Krown, KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJ, and Sabbadini RA. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 98: 2854-2865, 1996[Web of Science][Medline].

25.   Kubota, T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, and Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81: 627-635, 1997[Abstract/Free Full Text].

26.   Kurrelmeyer, KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N, Entman ML, and Mann DL. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 97: 5456-5461, 2000[Abstract/Free Full Text].

27.   Leibovici, L, Drucker M, Konigsberger H, Samra Z, Harrari S, Ashkenazi S, and Pitlik SD. Septic shock in bacteremic patients: risk factors, features and prognosis. Scand J Infect Dis 29: 71-75, 1997[Web of Science][Medline].

28.   Leri, A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, Malhotra A, Kajstura J, and Anversa P. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 101: 1326-1342, 1998[Web of Science][Medline].

29.   Lew, WYW, Lee M, Yasuda S, and Bayna E. Depyrogenation of digestive enzymes reduces lipopolysaccharide tolerance in isolated cardiac myocytes. J Mol Cell Cardiol 29: 1985-1990, 1997[Web of Science][Medline].

30.   Lew, WYW, Ryan J, and Yasuda S. Lipopolysaccharide induces cell shrinkage in rabbit ventricular cardiac myocytes. Am J Physiol Heart Circ Physiol 272: H2989-H2993, 1997[Abstract/Free Full Text].

31.   McDonald, TE, Grinman MN, Carthy CM, and Walley KR. Endotoxin infusion in rats induces apoptotic and survival pathways in hearts. Am J Physiol Heart Circ Physiol 279: H2053-H2061, 2000[Abstract/Free Full Text].

32.   Niebauer, J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, PA, Coats AJ, and Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353: 1838-1842, 1999[Web of Science][Medline].

33.   Opal, SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, and Lemke JH. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 180: 1584-1589, 1999[Web of Science][Medline].

34.   Pierzchalski, P, Reiss K, Cheng W, Cirielli C, Kajstura J, Nitahara JA, Rizk M, Capogrossi MC, and Anversa P. p53 Induces myocyte apoptosis via the activation of the renin-angiotensin system. Exp Cell Res 234: 57-65, 1997[Web of Science][Medline].

35.   Ravassa, S, Fortuno MA, Gonzalez A, Lopez B, Zalba G, Fortuno A, and Diez J. Mechanisms of increased susceptibility to angiotensin II-induced apoptosis in ventricular cardiomyocytes of spontaneously hypertensive rats. Hypertension 36: 1065-1071, 2000[Abstract/Free Full Text].

36.   Tamura, M, Chen YJ, Howard EF, Tanner M, Landon EJ, and Myers PR. Lipopolysaccharides and cytokines downregulate the angiotensin II type 2 receptor in rat cardiac fibroblasts. Eur J Pharmacol 386: 289-295, 1999[Web of Science][Medline].

37.   Tobias, PS, Tapping RI, and Gegner JA. Endotoxin interactions with lipopolysaccharide-responsive cells. Clin Infect Dis 28: 476-481, 1999[Web of Science][Medline].

38.   Wagner, DR, Combes A, McTiernan C, Sanders VJ, Lemster B, and Feldman AM. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-alpha. Circ Res 82: 47-56, 1998[Abstract/Free Full Text].

39.   Wagner, DR, McTiernan C, Sanders VJ, and Feldman AM. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation 97: 521-524, 1998[Abstract/Free Full Text].

40.   Wiedermann, CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, and Willeit J. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease. J Am Coll Cardiol 34: 1975-1981, 1999[Abstract/Free Full Text].

41.   Yasuda, S, and Lew WYW Lipopolysaccharide depresses cardiac contractility and beta -adrenergic contractile response by decreasing myofilament response to Ca2+ in cardiac myocytes. Circ Res 81: 1011-1020, 1997[Abstract/Free Full Text].

42.   Yasuda, S, and Lew WYW Angiotensin II exacerbates lipopolysaccharide-induced contractile depression in rabbit cardiac myocytes. Am J Physiol Heart Circ Physiol 276: H1442-H1449, 1999[Abstract/Free Full Text].

43.   Zeni, F, Freeman B, and Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25: 1095-1100, 1997[Web of Science][Medline].

Am J Physiol Heart Circ Physiol 283(2):H461-H467


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
X. Li, Y. Li, L. Shan, E Shen, R. Chen, and T. Peng
Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia
Cardiovasc Res, July 1, 2009; 83(1): 72 - 79.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Telemaque and J. L. Mehta
Sepsis, Calcineurin, and Cardiac Dysfunction: The Saga of Life and Death
J. Am. Coll. Cardiol., January 30, 2007; 49(4): 500 - 501.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. Suzuki, E. Bayna, H. L. Li, E. D. Molle, and W. Y.W. Lew
Lipopolysaccharide Activates Calcineurin in Ventricular Myocytes
J. Am. Coll. Cardiol., January 30, 2007; 49(4): 491 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Exp Biol MedHome page
N. Shimojo, S. Jesmin, S. Zaedi, M. Soma, S. Maeda, I. Yamaguchi, K. Goto, and T. Miyauchi
Changes in Important Apoptosis-Related Molecules in the Endothelin-1-Induced Hypertrophied Cardiomyocytes: Effect of the Pretreatment with Eicosapentaenoic Acid
Exp Biol Med, June 1, 2006; 231(6): 932 - 936.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Chao, Y. Shen, X. Zhu, H. Zhao, M. Novikov, U. Schmidt, and A. Rosenzweig
Lipopolysaccharide Improves Cardiomyocyte Survival and Function after Serum Deprivation
J. Biol. Chem., June 10, 2005; 280(23): 21997 - 22005.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
W. Y. W. Lew
Endotoxin attacks the cardiovascular system: Black death at the tollgate
J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1663 - 1665.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. Suzuki, E. Bayna, E. Dalle Molle, and W. Y. W. Lew
Nicotine inhibits cardiac apoptosis induced by lipopolysaccharide in rats
J. Am. Coll. Cardiol., February 5, 2003; 41(3): 482 - 488.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, H. L.
Right arrow Articles by Lew, W. Y. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, H. L.
Right arrow Articles by Lew, W. Y. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online